TEVA

Teva Pharmaceutical has closed its acquisition of Emalex Biosciences, adding ecopipam — a late-stage neuroscience asset — to its pipeline. Phase 3 data for ecopipam were recently published in JAMA Neurology, with a U.S. NDA submission expected in the second half of 2026. The deal is framed as part of Teva's broader "Pivot to Growth" strategy.

Teva Pharmaceutical has entered a definitive agreement to acquire Emalex Biosciences, a private company whose lead asset, ecopipam, is a first-in-class therapy for Tourette syndrome in children. Phase 3 data showed statistically significant results on the primary efficacy endpoint, with an NDA submission expected in the second half of 2026. The deal adds a near-regulatory-stage neuroscience asset to Teva's pipeline as part of its stated pivot-to-growth strategy.